An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer Academic Article uri icon

Overview

MeSH Major

  • Pteridines
  • Urologic Neoplasms

abstract

  • Volasertib as second-line treatment for advanced/metastatic UC had an acceptable safety profile but demonstrated insufficient antitumor activity for further evaluation as a monotherapy.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4696031

Digital Object Identifier (DOI)

  • 10.1002/cncr.28519

PubMed ID

  • 24339028

Additional Document Info

start page

  • 976

end page

  • 82

volume

  • 120

number

  • 7